- $11.2 million awarded to Clinical Trials Group through the $180.6 million Sovereign Industry Development Fund.
- The Crisafulli Government's investment has lured the Victoria-based company to expand into Queensland, creating more than 140 jobs.
- The Crisafulli Government is delivering a better lifestyle through a stronger economy by unlocking new opportunities, driving investment and supporting more jobs across Queensland.
The Crisafulli Government has lured Victoria-based Clinical Trial Group to set up shop in Queensland, investing $11.2 million through the flagship $180.6 million Sovereign Industry Development Fund.
Clinical Trials Group will expand into Queensland with the establishment of a new 40+ bed Phase 1 clinical trials research facility in Eight Mile Plains.
The facility will be able to run 24/7 to deliver first-in-human (FIH) and early-phase clinical trials for the domestic and international biomedical industry, creating more than 140 jobs and positioning Queensland as a market leader in the clinical trial space.
The $180.6 million Sovereign Industry Development Fund forms part of the Crisafulli Government's plan to revitalise Queensland's industrial base, attract private investment and secure long-term economic growth, by backing projects that are shovel-ready and will deliver lasting value to Queensland.
Unlike the former Labor Government's haphazard approach to industry development with 11 priority areas, including non-viable industries, the Crisafulli Government's $180.6 million Sovereign Industry Development Fund is helping build sovereign industry capability and leveraging Queensland's strengths in the re-focused State Development priorities of Biomedical, Defence and Biofuels.
Deputy Premier and Minister for State Development, Infrastructure and Planning, Jarrod Bleijie said the Sovereign Industry Development Fund was focused on delivery and backing investment‑ready projects that would deliver real sovereign capability, secure jobs and long‑term economic value for Queenslanders.
"Queensland is open for business, and the Crisafulli Government's investments are successfully luring more organisations to this great state," Deputy Premier Bleijie said.
"Unlike Labor's failed and haphazard approach to industry growth, these investments create jobs and drive industry development that secures Queensland's position as a global leader in biomedicine.
"Building sovereign capability has never been more critical, ensuring that Queensland is less reliant on global supply chains that can be disrupted by foreign conflicts, like we have seen recently.
"Queensland has strong foundations in biomedical research and innovation, and this funding will help Clinical Trials Group set up shop in the state, and support highly skilled jobs, advanced manufacturing and improved health resilience."
Clinical Trials Group CEO Jason Wagstaff said the expansion into Queensland would deliver new innovation and jobs in the state.
"This funding forms an important partnership with the Queensland Government to deliver research outcomes locally in Queensland," Mr Wagstaff said.
"The project enables Clinical Trials Group to deliver cutting edge clinical trials in Queensland, enabling access for participants while building and growing this crucial sector and supply chain. We are excited for Queensland to play a leading role in this space."
Clinical Trials Group has already secured leading, multinational healthcare and pharmaceutical organisation Sanofi as a user of the new facility.
Sanofi Global Head of Vaccines Research & Development Dr Jean-Francois Toussaint said the Crisafulli Government's support for biomedicine was a key drawcard for further investment in the state.
"Sanofi is delighted with the Queensland Government's $11.2 million investment in Clinical Trials Group's expansion into Queensland. It marks another significant step for the state's clinical research landscape, strengthening early - and late - phase trial capacity and expanding access to cutting edge research for patients," Dr Toussaint said.
"As R&D continues to underpin national prosperity, investments like this show how aligned policy, science and clinical ecosystems can position Queensland in a competitive global clinical trials environment. For Sanofi it reinforces the strength of our Translational Science Hub here in Brisbane and the state's ability to attract world-class research, create high-skilled jobs and connect patients with innovation."
This project complements two biomedical initiatives already supported under SIDF, together strengthening Queensland's end to end capability across research, clinical trials, advanced manufacturing and commercialisation.
